[{"id":"9c6947a9-7642-44d7-8cde-da7fb3ca0beb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05586360","created_at":"2022-10-19T13:56:32.222Z","updated_at":"2025-02-25T17:31:39.005Z","phase":"Phase 2","brief_title":"T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer","source_id_and_acronym":"NCT05586360","lead_sponsor":"Medical University of South Carolina","biomarkers":" FOXP3","pipe":"","alterations":" ","tags":["FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/11/2024","start_date":" 03/11/2024","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-01-30"},{"id":"ef502e78-36b6-4881-b791-586dbda2fa9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04379999","created_at":"2021-01-18T21:09:15.617Z","updated_at":"2024-07-02T16:34:26.352Z","phase":"Phase 1","brief_title":"Atorvastatin ± Aspirin in Lynch Syndrome Syndrome","source_id_and_acronym":"NCT04379999","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM • CASP3","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MLH1 • MSH6 • MSH2 • EPCAM • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-13"},{"id":"7cc580e8-c1f3-4929-85f2-d9ad42d412c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02968810","created_at":"2021-01-18T14:35:38.364Z","updated_at":"2024-07-02T16:35:09.555Z","phase":"Phase 2","brief_title":"Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis","source_id_and_acronym":"NCT02968810","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":" | ","alterations":" ALPL-H","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALPL-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 06/21/2017","start_date":" 06/21/2017","primary_txt":" Primary completion: 05/03/2023","primary_completion_date":" 05/03/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-16"},{"id":"eb1b4b01-c1ee-4614-a635-a45ea2b016b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03872388","created_at":"2021-01-18T19:05:38.473Z","updated_at":"2024-07-02T16:35:09.552Z","phase":"Phase 2","brief_title":"Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy","source_id_and_acronym":"NCT03872388","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • atorvastatin"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 01/14/2019","start_date":" 01/14/2019","primary_txt":" Primary completion: 10/19/2023","primary_completion_date":" 10/19/2023","study_txt":" Completion: 10/19/2023","study_completion_date":" 10/19/2023","last_update_posted":"2024-04-16"},{"id":"e61b2a2a-8b63-44e3-9ab5-9ad51bd15dc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03560882","created_at":"2021-01-18T17:31:32.363Z","updated_at":"2024-07-02T16:35:13.417Z","phase":"Phase 1","brief_title":"A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies","source_id_and_acronym":"NCT03560882","lead_sponsor":"Joaquina Baranda","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/19/2018","start_date":" 07/19/2018","primary_txt":" Primary completion: 10/14/2022","primary_completion_date":" 10/14/2022","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-03-21"},{"id":"de3e5ed5-da11-4b26-84b2-a20ffac47b50","acronym":"","url":"https://clinicaltrials.gov/study/NCT05338723","created_at":"2022-04-21T15:55:25.877Z","updated_at":"2024-07-02T16:35:17.398Z","phase":"Phase 3","brief_title":"Possible Protective Effect of Rosuvastatin in Chemotherapy-induced Cardiotoxicity in HER2 Positive Breast Cancer Patients","source_id_and_acronym":"NCT05338723","lead_sponsor":"Tanta University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 09/15/2020","start_date":" 09/15/2020","primary_txt":" Primary completion: 09/15/2023","primary_completion_date":" 09/15/2023","study_txt":" Completion: 09/15/2023","study_completion_date":" 09/15/2023","last_update_posted":"2024-02-28"},{"id":"3104beed-64b4-4837-ba0b-5ffd15be0444","acronym":"","url":"https://clinicaltrials.gov/study/NCT04767984","created_at":"2021-02-24T14:55:38.313Z","updated_at":"2024-07-02T16:35:22.455Z","phase":"Phase 2","brief_title":"Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis","source_id_and_acronym":"NCT04767984","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 09/24/2021","start_date":" 09/24/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-01-24"},{"id":"1ce44e77-8bde-42ee-b343-687c33a5fa41","acronym":"SIMPHONY","url":"https://clinicaltrials.gov/study/NCT03324425","created_at":"2021-01-18T16:25:00.670Z","updated_at":"2024-07-02T16:35:23.419Z","phase":"Phase 2","brief_title":"Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer","source_id_and_acronym":"NCT03324425 - SIMPHONY","lead_sponsor":"Baylor Breast Care Center","biomarkers":" ER","pipe":" | ","alterations":" HER-2 positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-01-15"},{"id":"97d926d0-be37-423b-83a2-cb239072fda6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05464810","created_at":"2022-07-19T14:54:34.432Z","updated_at":"2024-07-02T16:35:27.090Z","phase":"Phase 1","brief_title":"Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT05464810","lead_sponsor":"Emory University","biomarkers":" HER-2 • ER • PGR • IL6 • TNFA • IL10 • TGFB1","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER • PGR • IL6 • TNFA • IL10 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • simvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/02/2022","start_date":" 09/02/2022","primary_txt":" Primary completion: 04/15/2025","primary_completion_date":" 04/15/2025","study_txt":" Completion: 04/15/2025","study_completion_date":" 04/15/2025","last_update_posted":"2023-12-05"},{"id":"5e4173a0-f1b6-45fa-9023-3e3fc9e7ede2","acronym":"YAPPETIZER","url":"https://clinicaltrials.gov/study/NCT03358017","created_at":"2021-01-18T16:34:31.703Z","updated_at":"2024-07-02T16:35:32.529Z","phase":"Phase 2","brief_title":"Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer","source_id_and_acronym":"NCT03358017 - YAPPETIZER","lead_sponsor":"Mario Negri Institute for Pharmacological Research","biomarkers":" HER-2 • TP53 • PGR • BRCA • TAFAZZIN","pipe":" | ","alterations":" PGR negative","tags":["HER-2 • TP53 • PGR • BRCA • TAFAZZIN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zoledronic acid • atorvastatin"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 03/05/2018","start_date":" 03/05/2018","primary_txt":" Primary completion: 06/17/2021","primary_completion_date":" 06/17/2021","study_txt":" Completion: 07/25/2023","study_completion_date":" 07/25/2023","last_update_posted":"2023-10-19"},{"id":"3f7300d8-189d-4a32-8198-659823018d3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454529","created_at":"2021-02-22T06:52:45.002Z","updated_at":"2024-07-02T16:35:41.405Z","phase":"Phase 2","brief_title":"The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer","source_id_and_acronym":"NCT03454529","lead_sponsor":"Michael Simon","biomarkers":" HER-2 • PGR","pipe":"","alterations":" ","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 03/09/2018","start_date":" 03/09/2018","primary_txt":" Primary completion: 10/06/2021","primary_completion_date":" 10/06/2021","study_txt":" Completion: 10/06/2021","study_completion_date":" 10/06/2021","last_update_posted":"2023-08-01"},{"id":"400078f7-64d4-4277-9022-f03050a00674","acronym":"","url":"https://clinicaltrials.gov/study/NCT00840177","created_at":"2021-01-29T06:59:12.815Z","updated_at":"2024-07-02T16:35:49.076Z","phase":"Phase 2","brief_title":"S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia","source_id_and_acronym":"NCT00840177","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 115","initiation":"Initiation: 12/10/2009","start_date":" 12/10/2009","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 10/21/2021","study_completion_date":" 10/21/2021","last_update_posted":"2023-05-03"},{"id":"0832f425-1674-469e-b2f7-05cb2959cee1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05103644","created_at":"2021-11-02T17:57:09.080Z","updated_at":"2024-07-02T16:36:01.226Z","phase":"Phase 2/3","brief_title":"Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients\"","source_id_and_acronym":"NCT05103644","lead_sponsor":"Beni-Suef University","biomarkers":" HER-2 • WWTR1 • TAFAZZIN","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • WWTR1 • TAFAZZIN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/30/2021","start_date":" 10/30/2021","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2022-11-02"},{"id":"92a218df-d6c0-44fe-8a39-9c050b9e66de","acronym":"","url":"https://clinicaltrials.gov/study/NCT05550415","created_at":"2022-09-22T13:55:23.932Z","updated_at":"2024-07-02T16:36:03.476Z","phase":"Phase 2","brief_title":"The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer","source_id_and_acronym":"NCT05550415","lead_sponsor":"Indonesia University","biomarkers":" VIM","pipe":" | ","alterations":" VIM expression","tags":["VIM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VIM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 08/19/2022","start_date":" 08/19/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2022-09-26"},{"id":"6a14e8e5-6704-4f6d-8d3f-6ec8a3b0b562","acronym":"STARC","url":"https://clinicaltrials.gov/study/NCT02569645","created_at":"2022-06-04T12:54:03.426Z","updated_at":"2024-07-02T16:36:07.105Z","phase":"Phase 2","brief_title":"Rosuvastatin in the Treatment of Rectal Cancer","source_id_and_acronym":"NCT02569645 - STARC","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" RHOA • CDKN1A","pipe":"","alterations":" ","tags":["RHOA • CDKN1A"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 09/24/2021","primary_completion_date":" 09/24/2021","study_txt":" Completion: 09/24/2021","study_completion_date":" 09/24/2021","last_update_posted":"2022-07-20"},{"id":"9d269c50-cc6c-43a1-8de6-02054f537371","acronym":"","url":"https://clinicaltrials.gov/study/NCT04985201","created_at":"2021-08-02T14:52:59.493Z","updated_at":"2024-07-02T16:36:26.746Z","phase":"Phase 2","brief_title":"Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy","source_id_and_acronym":"NCT04985201","lead_sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • simvastatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 08/01/2023","study_completion_date":" 08/01/2023","last_update_posted":"2021-08-09"},{"id":"1bc77412-1b12-4c06-b2d8-c2e0007f9660","acronym":"","url":"https://clinicaltrials.gov/study/NCT04698941","created_at":"2021-01-19T20:50:04.276Z","updated_at":"2024-07-02T16:36:27.285Z","phase":"Phase 2","brief_title":"Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy","source_id_and_acronym":"NCT04698941","lead_sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • albumin-bound paclitaxel • simvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 07/25/2021","start_date":" 07/25/2021","primary_txt":" Primary completion: 12/30/2021","primary_completion_date":" 12/30/2021","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2021-07-29"},{"id":"a87e3c49-c60d-4e33-a7c5-006bbd064b96","acronym":"","url":"https://clinicaltrials.gov/study/NCT03826940","created_at":"2021-01-18T18:54:02.685Z","updated_at":"2024-07-02T16:36:32.463Z","phase":"","brief_title":"From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1","source_id_and_acronym":"NCT03826940","lead_sponsor":"University of Coimbra","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lovastatin"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 02/19/2019","start_date":" 02/19/2019","primary_txt":" Primary completion: 03/31/2020","primary_completion_date":" 03/31/2020","study_txt":" Completion: 08/31/2020","study_completion_date":" 08/31/2020","last_update_posted":"2021-04-02"},{"id":"41a97b99-65cc-4a02-b625-23a1ef7b344f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04776889","created_at":"2021-03-02T12:52:14.100Z","updated_at":"2024-07-02T16:36:33.889Z","phase":"Phase 4","brief_title":"The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients","source_id_and_acronym":"NCT04776889","lead_sponsor":"National Cancer Institute, Egypt","biomarkers":" EGFR • CAV1","pipe":"","alterations":" ","tags":["EGFR • CAV1"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 01/15/2019","start_date":" 01/15/2019","primary_txt":" Primary completion: 12/30/2020","primary_completion_date":" 12/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2021-03-02"},{"id":"767668bb-7660-4716-a504-9448522511e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04601116","created_at":"2021-01-19T20:30:28.646Z","updated_at":"2024-07-02T16:36:36.015Z","phase":"Phase 3","brief_title":"The MASTER Study (MAmmary Cancer STatin ER Positive Study)","source_id_and_acronym":"NCT04601116","lead_sponsor":"Aarhus University Hospital","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 3360","initiation":"Initiation: 01/04/2021","start_date":" 01/04/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2035","study_completion_date":" 01/01/2035","last_update_posted":"2021-01-14"},{"id":"fbf421ef-b893-4cba-ab92-9bfe9c4053dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04705909","created_at":"2021-01-19T20:51:31.076Z","updated_at":"2024-07-02T16:36:36.216Z","phase":"Phase 2/3","brief_title":"Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer","source_id_and_acronym":"NCT04705909","lead_sponsor":"Mansoura University","biomarkers":" CCND1 • CASP3","pipe":"","alterations":" ","tags":["CCND1 • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin • pitavastatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/15/2021","start_date":" 01/15/2021","primary_txt":" Primary completion: 09/15/2021","primary_completion_date":" 09/15/2021","study_txt":" Completion: 12/15/2021","study_completion_date":" 12/15/2021","last_update_posted":"2021-01-12"},{"id":"cfadf814-6011-48cb-93a2-6f8f551b1508","acronym":"ABC-SE","url":"https://clinicaltrials.gov/study/NCT02958852","created_at":"2021-01-18T14:32:07.915Z","updated_at":"2024-07-02T16:36:41.455Z","phase":"Phase 2","brief_title":"A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer","source_id_and_acronym":"NCT02958852 - ABC-SE","lead_sponsor":"Lund University Hospital","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • letrozole • atorvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2020-09-02"},{"id":"ceb13093-b87d-4535-863c-5b1f5ec5c206","acronym":"","url":"https://clinicaltrials.gov/study/NCT03086291","created_at":"2021-01-18T15:12:19.020Z","updated_at":"2024-07-02T16:36:52.025Z","phase":"Phase 1","brief_title":"A Phase I Study of High Dose Simvastatin in Patients With Gastrointestinal Tract Cancer Who Failed to Standard Chemotherapy","source_id_and_acronym":"NCT03086291","lead_sponsor":"Samsung Medical Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • NRAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin"],"overall_status":"Unknown status","enrollment":" Enrollment 9","initiation":"Initiation: 01/04/2018","start_date":" 01/04/2018","primary_txt":" Primary completion: 09/01/2020","primary_completion_date":" 09/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2019-12-30"},{"id":"9c655582-8e2f-460a-9a14-8195852475ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT04151355","created_at":"2021-01-18T20:15:56.016Z","updated_at":"2024-07-02T16:36:53.943Z","phase":"","brief_title":"Effect of Atorvastatin on 5-Fluorouracil Induced Mucositis","source_id_and_acronym":"NCT04151355","lead_sponsor":"Ain Shams University","biomarkers":" TNFA","pipe":"","alterations":" ","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • irinotecan • atorvastatin"],"overall_status":"Unknown status","enrollment":" Enrollment 100","initiation":"Initiation: 10/01/2019","start_date":" 10/01/2019","primary_txt":" Primary completion: 09/30/2020","primary_completion_date":" 09/30/2020","study_txt":" Completion: 09/30/2020","study_completion_date":" 09/30/2020","last_update_posted":"2019-11-05"}]